Last reviewed · How we verify
metaxalone m640
Metaxalone M640, marketed by Primus Pharmaceuticals, is a muscle relaxant with a key composition patent expiring in 2028. The drug's market position is bolstered by its established presence and lack of direct generic competition until the patent expiry. However, the primary risk lies in potential revenue erosion post-2028 due to the entry of generic competitors.
At a glance
| Generic name | metaxalone m640 |
|---|---|
| Also known as | Metaxalone 640 |
| Sponsor | Primus Pharmaceuticals |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Assess the Effect of Metaxalone 640 mg (M640) Compared to Tizanidine 8 mg on Truck Driving Ability and Cognition (PHASE4)
- Efficacy of M640 in Acute Lumbosacral Musculoskeletal Conditions. (PHASE4)
- Study to Assess Drowsiness, Cognition, Fall Risk After Metaxalone 640 mg and Metaxalone 800 mg (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |